Amgen (AMGN) Cash & Current Investments (2016 - 2025)
Historic Cash & Current Investments for Amgen (AMGN) over the last 17 years, with Q4 2025 value amounting to $9.1 billion.
- Amgen's Cash & Current Investments fell 2375.34% to $9.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $9.1 billion, marking a year-over-year decrease of 2375.34%. This contributed to the annual value of $9.1 billion for FY2025, which is 2375.34% down from last year.
- Per Amgen's latest filing, its Cash & Current Investments stood at $9.1 billion for Q4 2025, which was down 2375.34% from $9.4 billion recorded in Q3 2025.
- Amgen's 5-year Cash & Current Investments high stood at $34.7 billion for Q3 2023, and its period low was $6.5 billion during Q1 2022.
- Moreover, its 5-year median value for Cash & Current Investments was $9.4 billion (2022), whereas its average is $13.1 billion.
- As far as peak fluctuations go, Amgen's Cash & Current Investments soared by 38290.04% in 2023, and later crashed by 7406.23% in 2024.
- Amgen's Cash & Current Investments (Quarter) stood at $8.0 billion in 2021, then rose by 15.78% to $9.3 billion in 2022, then rose by 17.61% to $10.9 billion in 2023, then grew by 9.4% to $12.0 billion in 2024, then decreased by 23.75% to $9.1 billion in 2025.
- Its Cash & Current Investments was $9.1 billion in Q4 2025, compared to $9.4 billion in Q3 2025 and $8.0 billion in Q2 2025.